Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

These associations were not significant prior to IFNB treatment, and were not noticeably changed by gender, age, body mass index, HLA-DRB1*15, treatment group, compliance, or the concentrations of 25-hydroxyvitamin D, retinol, neutralising antibodies against IFNB, or the omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

The patients were followed for two years with repeated 12 magnetic resonance imaging (MRI) scans and nine serum measurements of alpha-tocopherol.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Alpha-tocopherol and MRI Outcomes in Multiple Sclerosis: Association and Prediction

Study design awaiting verification · PLoS ONE · 2013

Original publication title

Alpha-tocopherol and MRI Outcomes in Multiple Sclerosis: Association and Prediction

Kristin I. Løken-Amsrud; Kjell-Morten Myhr; Søren J. Bakke; Antonie G. Beiske; Kristian S. Bjerve; Bård T. Bjørnarå; Harald Hovdal; Finn Lilleås; Rune Midgard; Tom Pedersen; Jūratė Šaltytė Benth; Øivind Torkildsen; Stig Wergeland; Trygve Holmøy

© 2013 Løken-Amsrud et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

During treatment with IFNB, increasing serum concentrations of alpha-tocopherol were associated with reduced odds for simultaneous and subsequent MRI disease activity in RRMS patients.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

Alpha-tocopherol is the main vitamin E compound in humans, and has important antioxidative and immunomodulatory properties. The aim of this study was to study alpha-tocopherol concentrations and their relationship to disease activity in Norwegian multiple sclerosis (MS) patients.

Source: Objective

Abstract: What methods does the paper describe?

Prospective cohort study in 88 relapsing-remitting MS (RRMS) patients, originally included in a randomised placebo-controlled trial of omega-3 fatty acids (the OFAMS study), before and during treatment with interferon beta. The patients were followed for two years with repeated 12 magnetic resonance imaging (MRI) scans and nine serum measurements of alpha-tocopherol.

Source: Methods

Abstract: Results

During interferon beta (IFNB) treatment, each 10 µmol/L increase in alpha-tocopherol reduced the odds (CI 95%) for simultaneous new T2 lesions by 36.8 (0.5 to 59.8) %, p = 0.048, and for combined unique activity by 35.4 (1.6 to 57.7) %, p = 0.042, in a hierarchical regression model. These associations were not significant prior to IFNB treatment, and were not noticeably changed by gender, age, body mass index, HLA-DRB1*15, treatment group, compliance, or the concentrations of 25-hydroxyvitamin D, retinol, neutralising antibodies against IFNB, or the omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid.

The corresponding odds for having new T1 gadolinium enhancing lesions two months later was reduced by 65.4 (16.5 to 85.7) %, p = 0.019, and for new T2 lesions by 61.0 (12.4 to 82.6) %, p = 0.023.

Source: Results

Abstract: Conclusion

During treatment with IFNB, increasing serum concentrations of alpha-tocopherol were associated with reduced odds for simultaneous and subsequent MRI disease activity in RRMS patients.

Source: Conclusion
Authors’ abstract

Objective

Alpha-tocopherol is the main vitamin E compound in humans, and has important antioxidative and immunomodulatory properties. The aim of this study was to study alpha-tocopherol concentrations and their relationship to disease activity in Norwegian multiple sclerosis (MS) patients.

Methods

Prospective cohort study in 88 relapsing-remitting MS (RRMS) patients, originally included in a randomised placebo-controlled trial of omega-3 fatty acids (the OFAMS study), before and during treatment with interferon beta. The patients were followed for two years with repeated 12 magnetic resonance imaging (MRI) scans and nine serum measurements of alpha-tocopherol.

Results

During interferon beta (IFNB) treatment, each 10 µmol/L increase in alpha-tocopherol reduced the odds (CI 95%) for simultaneous new T2 lesions by 36.8 (0.5 to 59.8) %, p = 0.048, and for combined unique activity by 35.4 (1.6 to 57.7) %, p = 0.042, in a hierarchical regression model. These associations were not significant prior to IFNB treatment, and were not noticeably changed by gender, age, body mass index, HLA-DRB1*15, treatment group, compliance, or the concentrations of 25-hydroxyvitamin D, retinol, neutralising antibodies against IFNB, or the omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid.

The corresponding odds for having new T1 gadolinium enhancing lesions two months later was reduced by 65.4 (16.5 to 85.7) %, p = 0.019, and for new T2 lesions by 61.0 (12.4 to 82.6) %, p = 0.023.

Conclusion

During treatment with IFNB, increasing serum concentrations of alpha-tocopherol were associated with reduced odds for simultaneous and subsequent MRI disease activity in RRMS patients.

Publication and source details

Original title: Alpha-tocopherol and MRI Outcomes in Multiple Sclerosis: Association and Prediction

Kristin I. Løken-Amsrud; Kjell-Morten Myhr; Søren J. Bakke; Antonie G. Beiske; Kristian S. Bjerve; Bård T. Bjørnarå; Harald Hovdal; Finn Lilleås; Rune Midgard; Tom Pedersen; Jūratė Šaltytė Benth; Øivind Torkildsen; Stig Wergeland; Trygve Holmøy

PLoS ONE · 2013

* E-mail: trygve.holmoy@medisin.uio.no

Competing Interests: The study was partly supported by Merck-Serono, Pronova Biocare and Bayer Schering. Bård T. Bjørnarå is employed by Helsehuset Kongsberg, Finn Lilleås by Curato Oslo and Tom Pedersen by Unilabs. Kristin I. Løken-Amsrud has received travel support and an unrestricted research grant from Biogen Idec and travel support from Merck Serono. Kjell-Morten Myhr has received honoraria for lecturing, participation in pharmaceutical company sponsored clinical trials, and travel support from Bayer Schering, Biogen Idec, Novartis, Merck-Serono and Sanofi Aventis.

Harald Hovdal has participated in pharmaceutical company sponsored clinical trials and received travel support from Merck Serono, Biogen Idec and Bayer Schering. Rune Midgard has received honoraria for lecturing, participation in pharmaceutical company sponsored clinical trials, and travel support from Bayer Schering, Biogen Idec, Novartis, Merck-Serono and Sanofi Aventis. Stig Wergeland has received speaker honoraria and travel support from Sanofi Aventis, Biogen Idec, Bayer Schering and Novartis. Trygve Holmøy has received speaker honoraria and travel support from Sanofi Aventis, Biogen Idec, Bayer Schering, Novartis and Merck Serono.

There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

Conceived and designed the experiments: KMM SJB AGB KSB BTB HH FL RM TP TH. Analyzed the data: KILA JSB TH. Contributed reagents/materials/analysis tools: KSB. Wrote the paper: KILA TH. Contributed by interpretation of the data and revising the manuscript: KMM SJB AGB KSB BTB HH FL RM TP ØT SW.

© 2013 Løken-Amsrud et al2013Løken-Amsrud et alhttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.The study was supported by Merck-Serono, Pronova Biocare, Bayer Schering, Innlandet Hospital Trust (Grant number 150164), The Western Norway Regional Health Authority, Odd Fellow Research Foundation for multiple sclerosis, Kåre Wærner’s Legacy and The Norwegian MS Society. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T13:24:10.771885+00:00

DOI: 10.1371/journal.pone.0054417 · PMC3551804